Trevi Therapeutics, Inc. (TRVI): R&D Expense
$33.48M
Year ended 2025-12-31
$41.37M
Trailing 12 months to 2026-06-30
+19.1%
3-year compound annual growth
+8.4%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $33.48M | -15.0% | 2026-03-17, From 2025-01-01 |
| 2024-12-31 | $39.38M | +66.3% | 2026-03-17, From 2024-01-01 |
| 2023-12-31 | $23.68M | +19.4% | 2025-03-18, From 2023-01-01 |
| 2022-12-31 | $19.83M | -13.7% | 2024-03-20, From 2022-01-01 |
| 2021-12-31 | $22.98M | +2.9% | 2023-03-16, From 2021-01-01 |
| 2020-12-31 | $22.33M | +15.5% | 2022-03-17, From 2020-01-01 |
| 2019-12-31 | $19.34M | +37.4% | 2021-03-25, From 2019-01-01 |
| 2018-12-31 | $14.07M | n/a | 2020-03-16, From 2018-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Trevi Therapeutics, Inc. (TRVI) | 2025-12-31 | $33.48M | -15.0% |
| Adicet Bio, Inc. (ACET) | 2025-12-31 | $99.13M | -0.2% |
| Foghorn Therapeutics Inc. (FHTX) | 2025-12-31 | $85.47M | -9.6% |
| UroGen Pharma Ltd. (URGN) | 2025-12-31 | $67.11M | +17.4% |
| Fortress Biotech, Inc. (FBIO) | 2025-12-31 | $11.90M | -79.0% |
| Lexicon Pharmaceuticals, Inc. (LXRX) | 2025-12-31 | $61.12M | -27.7% |
| Alto Neuroscience, Inc. (ANRO) | 2025-12-31 | $45.62M | -2.9% |
| Benitec Biopharma Inc. (BNTC) | 2026-06-30 | $23.39M | +27.6% |
| COMPASS Pathways plc (CMPS) | 2025-12-31 | $118.44M | -0.5% |
Compare TRVI, ACET, FHTX, URGN side by side · Screen every company in Pharmaceutical Preparations ↗